Warning: The NCBI web site requires JavaScript to function. more...
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.
Möller B, Aeberli D, Eggli S, Fuhrer M, Vajtai I, Vögelin E, Ziswiler HR, Dahinden CA, Villiger PM.
Arthritis Res Ther. 2009;11(3):R62. Epub 2009 May 6.
Related citations
Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.
Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599.
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.
Arthritis Rheum. 2006 Feb;54(2):613-20.
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT.
Arthritis Res Ther. 2009;11(4):R131. Epub 2009 Aug 28.
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.
Ann Rheum Dis. 2009 Jun;68(6):1011-6. Epub 2008 Jul 22.
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP.
Arthritis Rheum. 2006 Aug;54(8):2377-86.
Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.
Scand J Immunol. 2004 Jul-Aug;60(1-2):209-18.
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M.
Arthritis Res Ther. 2009;11(4):R123. Epub 2009 Aug 17.
Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
Vital EM, Dass S, Rawstron AC, Buch MH, Goëb V, Henshaw K, Ponchel F, Emery P.
Arthritis Rheum. 2010 May;62(5):1273-9.
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P, Dörner T, Tony HP.
Arthritis Rheum. 2008 Jun;58(6):1566-75.
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.
Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE.
Arthritis Res Ther. 2009;11(3):R84. Epub 2009 Jun 5.
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.
Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P.
Arthritis Rheum. 2008 Oct;58(10):2993-9.
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
Arthritis Rheum. 2007 May;56(5):1417-23.
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC.
Arthritis Rheum. 2006 Mar;54(3):723-32.
New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M, Vannucchi G, Campi I, Currò N, Beck-Peccoz P.
Ann Endocrinol (Paris). 2008 Apr;69(2):153-6. Epub 2008 Apr 15.
Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.
Muhammad K, Roll P, Einsele H, Dörner T, Tony HP.
Arthritis Rheum. 2009 Aug;60(8):2284-93.
Improvement of refractory rheumatoid arthritis after depletion of B cells.
Kneitz C, Wilhelm M, Tony HP.
Scand J Rheumatol. 2004;33(2):82-6.
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP.
Drugs. 2003;63(8):803-43. Review.
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
Arthritis Rheum. 2007 Dec;56(12):3909-18.
Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation.
Cepok S, von Geldern G, Grummel V, Hochgesand S, Celik H, Hartung H, Hemmer B.
J Neuroimmunol. 2006 Nov;180(1-2):33-9. Epub 2006 Sep 6.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on